To investigate disease burden and unmet needs in IBD patients receiving advanced therapies in Greece.
Approach:
Data Collection: Patients completed a structured self-reported questionnaire collecting sociodemographic data, smoking status, comorbidities, disease activity, current medications, and patient-reported outcomes (PROs) including the Short Inflammatory Bowel Disease Questionnaire (SIBDQ), Work Productivity and Activity Impairment (WPAI), and Patient Health Questionnaire-9 (PHQ-9).
Key Findings:
Among 287 patients with IBD (201 with CD, 86 with UC) receiving advanced therapies, 57.1% had active disease.
76.4% reported impaired quality of life (QoL).
30.3% experienced work productivity loss.
38.4% reported activity impairment.
39.1% expressed dissatisfaction with their advanced therapy.
10.9% reported reduced adherence to treatment.
Interpretation:
Higher disease activity was associated with worse QoL, greater work impairment, increased depressive symptoms, and lower treatment satisfaction.
Limitations:
The study is limited to patients receiving advanced therapies in Greece.
Data may not fully capture the multidimensional burden of IBD.
Conclusion:
Despite advanced therapies, IBD burden remains substantial among Greek patients, with significant dissatisfaction reported.
